In a recent overview of the pharmaceutical landscape, it has been noted that while Trump has successfully negotiated price deals with 16 drug companies, these companies are still planning to raise prices on approximately 350 medications this year. As the U.S. pharmaceutical industry adapts to the Most-Favored-Nation (MFN) pricing policy, European leaders are being warned about potential ramifications for their drug pricing models. The MFN approach is expected to shape future pricing strategies, with many drugmakers preparing for heightened negotiations not just in the U.S. but also in Europe. Despite the push for lower drug prices in the U.S., experts argue that the logic behind these efforts may be flawed, leading to complicated dynamics in international pricing. As this situation evolves, the pressure on European drug pricing systems is likely to increase due to the impact of recent U.S. pricing deals.